Login to Your Account



Clinic Roundup


Friday, February 15, 2013
• BioAlliance Pharma SA, of Paris, said the FDA approved a U.S. extension of its Phase II trial of Validive (clonidine Lauriad) for the prevention of radio/chemotherapy-induced oral mucositis in patients with head and neck cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription